Diabetic Medicine 2012; 29(5): 690-6921

Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

K. Y. Thong¹ , R. E. J. Ryder¹ , M. L. Cull¹ and C. Walton² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

²Diabetes, Hull Royal Infirmary, Hull, UK

^†List of contributors, see Supporting Information, Appendix S2